ClinicalTrials.gg
RecruitingNCT05024188Updated Oct 13, 2026

Assessing the Potential Role of the Gut Microbiome in Modulating Physical Abilities in Humans

An interventional study of Antibiotics and Autologous Fecal Microbiota Transplantation in Physical Abilities and FMT, sponsored by Assaf-Harofeh Medical Center. Recruiting at 1 site in Israel. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Assaf-Harofeh Medical Center · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Updated Oct 13, 2026Now RecruitingFirst site in Israel+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The intestinal microbiome is a microbial system that is influenced by host genetics and environmental exposures such as nutrition, stress and medications. There is a growing body of evidence indicating the significant contribution of the gut microbiome to host health and disease. Furthermore, it has been shown that exercise may modify the microbiome composition. However, important mechanistic questions related to the possible associations between exercise and the human gut microbiome remain unanswered.

In this study, the investigators are using advanced state-of-the-art measurements of physical activity level and related metabolic parameters whether there is a connection between the microbiome and physical abilities in healthy participants and whether antibiotics consumption can influence host physical abilities and glycemic responses through changes induced in microbiome composition and function.

Read the detailed description

In this interventional study participants will be followed by researchers for up to 1 month. During all days of the study participants will be connected to a continuous glucose monitor (CGM). During the study, participants will collect stool and buccal samples which will be used for microbiota profiling. Participants will receive kits in advance to collect the stool, and oral sample at home. Additionally, participants will receive a Smartwatch to track their physical activity performance.

In the second segment of the study, participants will be randomized into two groups: antibiotics or placebo, which will be consumed for 7 days.

The third segment of the trial, Participants will be allocated into three groups, to receive either 15 Autologous fecal microbiota transplantation (aFMT) capsules or 15 identical placebo capsules (participants who received antibiotics will be divided into 2 groups to receive fecal microbiota transplantation (FMT) or placebo, and participants who received placebo will receive placebo in this segment as well). The FMT will take place for two consecutive days (a total of 30 capsules).

On the fourth meeting After all tests are done, participants who received antibiotic and haven't received aFMT will undergo an FMT administration (on meetings 4-5). The FMT will take place on two consecutive days (a total of 30 capsules) in the same manner it was described above. The other 2 groups will receive a placebo capsules as described above.

Participants will undergo physical abilities tests (VO2max test, muscle strength will be valued with "System 4 Pro™ BIODEX " or a manual dynamometer, high jumps, 30 seconds jumps, flexibility. Before, immediately after, and following 1,3, 5, 7 and 9 minutes of the 30 seconds jumps, finger prick blood samples will be taken for lactate measurement), anthropometric measurements, medical history questioners, blood samples and body composition using DXA.

All adverse events will be documented and reported as necessary to the study doctor and the ethical committee.

An additional cohort of 18 days (group b) will be recruited in order to examine the role of the gut microbiome in contributing to exercise capacity, particularly through D-lactate generation.

Participants will be asked to perform cycles of 4-minute efforts, increasing capacity by 10-15% per stage. Blood lactate at the end of each stage will be collected. Cycles will stop once the participant reached their lactate threshold, monitered by the finger prick lactate measurement and or if the participant cannot sustain the workload. Similarly to the first cohort, participants will be randomized to receive either antibiotics or placebo. Participants in the antibiotics arm will receive their aFMT to restore their pre-antibiotic gut microbiome, by ingesting 30 pills of FMT, and the placebo group will receive 30 pills of Cellulose.

02

Conditions studied

  • Physical Abilities
  • FMT
03

In context

Lead sponsor

Assaf-Harofeh Medical Center is the lead sponsor of 267 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age - 20-55
  • Are used to exercise in aerobic sports (running, swimming, 'zumba', ball games, functional training, surfing, tennis, wrestling ext.).
  • Exercise at least twice a week, for a minimum duration of the last 6 months.

Exclusion criteria

Exclusion Criteria:

  • Consumption of antibiotics (PO) or probiotics 3 months prior to the first day of the experiment.
  • Diagnosis of type 1 or type 2 diabetes.
  • Pregnancy, fertility treatments, breastfeeding women six months prior to enrollment and during the study.
  • Chronic disease-under the discretion of the study medical team (e.g. AIDS, Cushing syndrome, Chronic kidney disease (CKD), acromegaly, hyperthyroidism etc.)
  • Cancer and recent anticancer treatment
  • Psychiatric disorders
  • Coagulation disorders
  • Gastrointestinal disorders
  • Bariatric surgery
  • Alcohol or substance abuse
  • Any physical condition precluding the completion of a routine effort test
  • Allergy to Flagyl (Metronidazole) and/ or Ciprodex (Ciprofloxacin)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Antibiotics + FMT

    7 days of antibiotics- Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 15 aFMT capsules for two consecutive days (a total of 30 capsules). On the forth + fifth meeting, participants who received antibiotic FMT will receive a 30 placebo capsules

    Drug: Antibiotics · Other: Autologous Fecal Microbiota Transplantation · Other: placebo capsules

  • Placebo comparator
    Placebo

    7 days of placebo cellulose pills. After cellulose pills administration, participants will receive 15 placebo capsules for two consecutive days (a total of 30 capsules). On the forth + fifth meeting, the participants will again receive 30 placebo capsules.

    Other: Cellules Pills · Other: placebo capsules

  • Experimental
    Antibiotics+placebo

    7 days of antibiotics- Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration participants will receive 15 placebo capsules. On the forth + fifth meeting the participants will receive 15 aFMT capsules for two consecutive days (a total of 30 capsules).

    Drug: Antibiotics · Other: Autologous Fecal Microbiota Transplantation · Other: placebo capsules

Interventions

  • DrugAntibiotics

    Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.

    Also known as: Ciprofloxacin & Metronidazole

  • OtherAutologous Fecal Microbiota Transplantation

    Autologous Fecal Microbiota Transplantation( aFMT( stool taken from the participant, prior to antibiotic treatment)

    Also known as: FMT

  • OtherCellules Pills

    7 days of cellules placebo pills.

  • Otherplacebo capsules

    Placebo capsules consist of saline/glycerol (the same vehicle as in a FMT capsules)

06

What researchers measure

Primary outcomes

  1. Microbiome Profiling

    Using stool and buccal samples for microbiome composition analysis

    Time frame: 1 month

  2. Physical ability

    will be measured by several tests: flexibility, Biodex, maximal oxygen uptake (VO2 max), high jumps, 30 seconds jumps, lactate measurement.

    Time frame: 1 month

Secondary outcomes

  1. Glycemic Responses

    Performing continuous glucose monitor (CGM)

    Time frame: 1 month

Other outcomes

  1. D- lactate measurement

    measuring D-Lactate threshold

    Time frame: 18 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Clarke SF, Murphy EF, O'Sullivan O, Lucey AJ, Humphreys M, Hogan A, Hayes P, O'Reilly M, Jeffery IB, Wood-Martin R, Kerins DM, Quigley E, Ross RP, O'Toole PW, Molloy MG, Falvey E, Shanahan F, Cotter PD. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014 Dec;63(12):1913-20. doi: 10.1136/gutjnl-2013-306541. Epub 2014 Jun 9. PubMed 25021423 ↗
  • Barton W, Penney NC, Cronin O, Garcia-Perez I, Molloy MG, Holmes E, Shanahan F, Cotter PD, O'Sullivan O. The microbiome of professional athletes differs from that of more sedentary subjects in composition and particularly at the functional metabolic level. Gut. 2018 Apr;67(4):625-633. doi: 10.1136/gutjnl-2016-313627. Epub 2017 Mar 30. PubMed 28360096 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2022 (actual). Primary completion is estimated for Dec 2028, 78 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jan 2022 → Jun 2022, primary completion Jul 2022 → Dec 2028 and completion Jan 2023 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 27, 2021
StartActual
Jun 29, 2022was Jan 2022
Primary completionEst.
Dec 31, 2028was Jul 2022
CompletionEst.
Dec 31, 2029was Jan 2023
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Oct 13, 2026
Sites
1 site added — first site in Israel
Show site
  • Weizmann Institute of Science · Rehovot, Israel
Oct 13, 2026
Start date
Jan 20, 2022→Jun 29, 2022 (actual)
Oct 13, 2026
Primary completion
Jul 20, 2022→Dec 31, 2028
Oct 13, 2026
Study completion
Jan 20, 2023→Dec 31, 2029
Oct 13, 2026
Enrollment
50→70
Oct 13, 2026
Eligibility
Maximum age 35 Years→55 Years; 2 inclusion criteria edited, 1 removed; 1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedBMI<28
  • EditedAge - 20-3555
  • EditedAre used to exercise in aerobic sports (running, swimming, Zumba'zumba', ball games, functional training, surfing, tennis, wrestling ext.).
Exclusion criteria
  • EditedChronic disease-under the discretion of the study medical team (e.g. AIDS, Cushing syndrome, Chronic kidney disease (CKD), acromegaly, hyperthyroidism etc.)
  • RemovedBMI>28
  • AddedAllergy to Flagyl (Metronidazole) and/ or Ciprodex (Ciprofloxacin)
Oct 13, 2026
Interventions
Changed Fecal Microbiota Transplantation→Autologous Fecal Microbiota Transplantation. Added placebo capsules; removed Agarose Capsules. Arms added: Antibiotics+placebo
Oct 13, 2026
Primary outcomes
1 time frame changed, 1 added, 2 removed, 1 description edited
What changed in the outcomes
  • AddedPhysical abilityTime frame: 1 month
  • RemovedBody Mass Index (BMI)Time frame: 2 years
  • RemovedBody CircumferencesTime frame: 2 years
  • Time frameMicrobiome Profiling2 years → 1 month
  • DescriptionMicrobiome Profiling: how it is measured was reworded
Oct 13, 2026
Secondary outcomes
1 time frame changed, 1 added, 1 removed
What changed in the outcomes
  • RemovedBone Mineral Density (BMD)Time frame: 2 years
  • Time frameGlycemic Responses2 years → 1 month
  • Addedother outcomeD- lactate measurementTime frame: 18 days
Oct 13, 2026
Sponsor
Assaf Harofeh MC→Assaf-Harofeh Medical Center; Collaborators added: Wingate Institute
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Status unknown→Recruiting
    1 site added — first site in Israel
    Show site
    • Weizmann Institute of Science · Rehovot, Israel
    Start date Jan 20, 2022→Jun 29, 2022 (now actual)
    Primary completion Jul 20, 2022→Dec 31, 2028
    Study completion Jan 20, 2023→Dec 31, 2029
    Enrollment 50→70
    Eligibility Maximum age 35 Years→55 Years; 2 inclusion criteria edited, 1 removed; 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedBMI<28
    • EditedAge - 20-3555
    • EditedAre used to exercise in aerobic sports (running, swimming, Zumba'zumba', ball games, functional training, surfing, tennis, wrestling ext.).
    Exclusion criteria
    • EditedChronic disease-under the discretion of the study medical team (e.g. AIDS, Cushing syndrome, Chronic kidney disease (CKD), acromegaly, hyperthyroidism etc.)
    • RemovedBMI>28
    • AddedAllergy to Flagyl (Metronidazole) and/ or Ciprodex (Ciprofloxacin)
    Primary outcomes 1 time frame changed, 1 added, 2 removed, 1 description edited
    What changed in the outcomes
    • AddedPhysical abilityTime frame: 1 month
    • RemovedBody Mass Index (BMI)Time frame: 2 years
    • RemovedBody CircumferencesTime frame: 2 years
    • Time frameMicrobiome Profiling2 years → 1 month
    • DescriptionMicrobiome Profiling: how it is measured was reworded
    Secondary outcomes 1 time frame changed, 1 added, 1 removed
    What changed in the outcomes
    • RemovedBone Mineral Density (BMD)Time frame: 2 years
    • Time frameGlycemic Responses2 years → 1 month
    • Addedother outcomeD- lactate measurementTime frame: 18 days
    Interventions Changed Fecal Microbiota Transplantation→Autologous Fecal Microbiota Transplantation. Added placebo capsules; removed Agarose Capsules. Arms added: Antibiotics+placebo
    Sponsor Assaf Harofeh MC→Assaf-Harofeh Medical Center; Collaborators added: Wingate Institute
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05024188
Collaborators
Weizmann Institute of Science, Wingate Institute
Responsible party
Ilan Youngster (Manager- Microbiome Center, Assaf-Harofeh Medical Center) — Principal investigator
First posted
Aug 27, 2021
Start date
Jun 29, 2022
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Ilan Youngster, Dr.
Contact
youngsteri@asaf.health.gov.il
+972-50630119
Ilan Youngster, Dr.
principal investigator · Assaf-Harofeh MC, Bee'r Yaakov Israel

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion